A case report of drug interaction between co-packaged nirmatrelvir-ritonavir and tacrolimus causing hyponatremia in a lung transplant recipient

Chien-Ming Lo,Wei-Hsun Chen,Meng-Yun Tsai,Hung-I Lu,Yu-Hsin Hsiao,Kai-Hao Chuang,Yu Chen,Hsuan-Feng Wu,Kuo-Tung Huang,Yi-Hsi Wang

DOI: https://doi.org/10.1186/s13019-024-02599-w

2024-03-17

Journal of Cardiothoracic Surgery

Abstract:Coronavirus disease 2019 (COVID-19) infection in lung transplant recipients can be lethal owing to the use of immunosuppressants. Antiviral agents may be administered to these patients. Co-packaged nirmatrelvir-ritonavir is a new agent currently being used in combination.

surgery,cardiac & cardiovascular systems

What problem does this paper attempt to address?

The problem that this paper attempts to solve is the possible drug - interaction problem between nirmatrelvir - ritonavir (a drug combination for treating COVID - 19) and the immunosuppressant tacrolimus in lung transplant recipients. Specifically, through a case report, the paper shows that a 64 - year - old female lung transplant recipient developed hyponatremia and an increase in tacrolimus blood concentration after using nirmatrelvir - ritonavir. The researchers hope to emphasize through this case that when using nirmatrelvir - ritonavir in lung transplant recipients, the blood concentration of tacrolimus needs to be closely monitored to avoid serious adverse reactions, such as hyponatremia and acute kidney injury.

The paper also discusses the possible mechanism of this drug - interaction, pointing out that ritonavir in nirmatrelvir - ritonavir is a potent CYP3A inhibitor, and tacrolimus is mainly metabolized through CYP3A4 and CYP3A5, so it may lead to a significant increase in the blood concentration of tacrolimus, thereby causing side effects such as hyponatremia. The researchers suggest that in cases where it is necessary to use this drug combination, the dose of tacrolimus should be reduced and its blood concentration should be closely monitored. In addition, more similar case reports are needed to further confirm the existence of this drug - interaction and its impact.